The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Prostate Cancer Stem Cells: A New Target for Therapy
Abstract
The existence of prostate cancer stem cells offers a theoretical explanation for many of the enduring uncertainties surrounding the etiology and treatment of the most commonly diagnosed tumor in US males. The study of cancer stem cells in prostate, as in other complex tissues, is critically dependent on the availability of pure cell populations, a situation complicated by the heterogeneity of prostate tumors. However, selection of cells with a CD133+/α2β1 integrin/ CD44+ phenotype enriches for a tumor-initiating population from human prostate cancers. Among the most pressing needs is for enduring therapy in patients who have experienced failure of hormonal treatments. Because the putative cancer stem cell does not express androgen receptor, it is likely to be immune from most androgen-based therapies, and an inherent genetic instability would enable the tumor to develop the new variants present in hormone-refractory disease. Prostate cancer stem cells have a unique gene expression signature that can also be related to Gleason grade and patient outcome. The scarcity of cancer stem cells in a prostate tumor will probably limit their usefulness in cancer diagnosis and prognosis. However, the emergence of new stem-cell therapeutic targets not only will require new assays for efficacy (because of their relatively quiescent nature), but also holds real promise of more lasting treatments to augment those currently directed against the remaining tumor cells, which comprise 99.9% of tumor mass, but paradoxically have a poor tumor-initiating capacity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Prospective Identification of Tumorigenic Prostate Cancer Stem Cells
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2018 · Cited by 2,820
Self-citationThe polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
A molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Inflammation in prostate carcinogenesis
De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2090 · Cited by 1,621
Classification of prostatic carcinomas.
Gleason, D. F. (1966) · PubMed · Cited by 1,110
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Patrawala, L., Calhoun, T., Schneider-Broussard, R., Li, H., Bhatia, B., Tang, S., Reilly, J. G., Chandra, D., Zhou, J., Claypool, K., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209327 · Cited by 968
Hedgehog signalling in prostate regeneration, neoplasia and metastasis
Karhadkar, S. S., Steven Bova, G., Abdallah, N., Dhara, S., Gardner, D., Maitra, A., Isaacs, J. T., Berman, D. M., & Beachy, P. A. (2004) · Nature · doi:10.1038/nature02962 · Cited by 950
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844
Mendelian inheritance of familial prostate cancer.
Carter, B. S., Beaty, T. H., Steinberg, G. D., Childs, B., & Walsh, P. C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3367 · Cited by 781
CD133, a novel marker for human prostatic epithelial stem cells
Richardson, G. D., Robson, C. N., Lang, S. H., Neal, D. E., Maitland, N. J., & Collins, A. T. (2004) · Journal of Cell Science · doi:10.1242/jcs.01222 · Cited by 770
Self-citationDD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer
Hessels, D., Klein Gunnewiek, J. M. T., van Oort, I., Karthaus, H. F. M., van Leenders, G. J. L., van Balken, B., Kiemeney, L. A., Witjes, J. A., & Schalken, J. A. (2003) · European Urology · doi:10.1016/s0302-2838(03)00201-x · Cited by 704
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., Lilja, H., Schwartz, L., Larson, S., Fleisher, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1506 · Cited by 665
Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S., Karthaus, H. F. M., Schaafsma, H. E., Debruyne, F. M. J., & Isaacs, W. B. (1992) · PubMed · Cited by 611
p63 Is a Prostate Basal Cell Marker and Is Required for Prostate Development
Signoretti, S., Waltregny, D., Dilks, J., Isaac, B., Lin, D., Garraway, L., Yang, A., Montironi, R., McKeon, F., & Loda, M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64814-6 · Cited by 610
Etiology and disease process of benign prostatic hyperplasia
Isaacs, J. T., & Coffey, D. S. (1989) · The Prostate · doi:10.1002/pros.2990150506 · Cited by 558
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Walsh, P. C. (2002) · PubMed · Cited by 477
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
Attard, G., Clark, J., Ambroisine, L., Fisher, G., Kovacs, G., Flohr, P., Berney, D., Foster, C. S., Fletcher, A., Gerald, W. L., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210640 · Cited by 438
Miki, J., Furusato, B., Li, H., Gu, Y., Takahashi, H., Egawa, S., Sesterhenn, I. A., McLeod, D. G., Srivastava, S., & Rhim, J. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4429 · Cited by 369
Collins, A. T., Habib, F. K., Maitland, N. J., & Neal, D. E. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.21.3865 · Cited by 357
Self-citationShmelkov, S. V., St.Clair, R., Lyden, D., & Rafii, S. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.08.010 · Cited by 348
Patrawala, L., Calhoun-Davis, T., Schneider-Broussard, R., & Tang, D. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0490 · Cited by 346
Prostate Cancer Cells with Stem Cell Characteristics Reconstitute the Original Human Tumor In vivo
Gu, G., Yuan, J., Wills, M., & Kasper, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4608 · Cited by 343
Global Gene Expression Profiling of Circulating Tumor Cells
Smirnov, D. A., Zweitzig, D. R., Foulk, B. W., Miller, M. C., Doyle, G. V., Pienta, K. J., Meropol, N. J., Weiner, L. M., Cohen, S. J., Moreno, J. G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4330 · Cited by 329
Rocchi, P., So, A., Kojima, S., Signaevsky, M., Beraldi, E., Fazli, L., Hurtado-coll, A., Yamanaka, K., & Gleave, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3998 · Cited by 316
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis.
Meeker, A. K., Hicks, J. L., Platz, E. A., March, G. E., Bennett, C., Delannoy, M. J., & Marzo, A. M. D. (2002) · PubMed · Cited by 313
Transformation of Different Human Breast Epithelial Cell Types Leads to Distinct Tumor Phenotypes
Ince, T. A., Richardson, A. L., Bell, G. W., Saitoh, M., Godar, S., Karnoub, A. E., Iglehart, J. D., & Weinberg, R. A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.06.013 · Cited by 309
Androgen receptor mutations in prostate cancer.
Barrack, E. R. (1996) · PubMed · Cited by 300
Role of stroma in carcinogenesis of the prostate
Cunha, G. R., Hayward, S. W., & Wang, Y. Z. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700902.x · Cited by 298
A molecular correlate to the Gleason grading system for prostate adenocarcinoma
True, L., Coleman, I., Hawley, S., Huang, C.-Y., Gifford, D., Coleman, R., Beer, T. M., Gelmann, E., Datta, M., Mostaghel, E., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603678103 · Cited by 291
Ao, M., Franco, O. E., Park, D., Raman, D., Williams, K., & Hayward, S. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3946 · Cited by 278
Genomic Profiling Reveals Alternative Genetic Pathways of Prostate Tumorigenesis
Lapointe, J., Li, C., Giacomini, C. P., Salari, K., Huang, S., Wang, P., Ferrari, M., Hernandez-Boussard, T., Brooks, J. D., & Pollack, J. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0673 · Cited by 269
Targeted therapy for cancer stem cells: the patched pathway and ABC transporters
Lou, H., & Dean, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210200 · Cited by 239
Noninvasive Detection of TMPRSS2:ERG Fusion Transcripts in the Urine of Men with Prostate Cancer
Laxman, B., Tomlins, S. A., Mehra, R., Morris, D. S., Wang, L., Helgeson, B. E., Shah, R. B., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2006) · Neoplasia · doi:10.1593/neo.06625 · Cited by 239
Circulating tumor cells predict survival in patients with metastatic prostate cancer
Moreno, J. G., Miller, M. C., Gross, S., Allard, W. J., Gomella, L. G., & Terstappen, L. W. M. M. (2005) · Urology · doi:10.1016/j.urology.2004.11.006 · Cited by 223
Intermediate Cells in Human Prostate Epithelium Are Enriched in Proliferative Inflammatory Atrophy
van Leenders, G. J. L. H., Gage, W. R., Hicks, J. L., van Balken, B., Aalders, T. W., Schalken, J. A., & De Marzo, A. M. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64286-1 · Cited by 212
Birnie, R., Bryce, S. D., Roome, C., Dussupt, V., Droop, A., Lang, S. H., Berry, P. A., Hyde, C. F., Lewis, J. L., Stower, M. J., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-5-r83 · Cited by 212
Self-citationRole of p63 and basal cells in the prostate
Kurita, T., Medina, R. T., Mills, A. A., & Cunha, G. R. (2004) · Development · doi:10.1242/dev.01384 · Cited by 204
Collins, A. T., & Maitland, N. J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.037 · Cited by 198
Self-citationDarwinian medicine: a case for cancer
Greaves, M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2071 · Cited by 180
Hudson, D. L., Guy, A. T., Fry, P., O'Hare, M. J., Watt, F. M., & Masters, J. R. W. (2001) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540104900214 · Cited by 168
Berezovska, O. P., Glinskii, A. B., Yang, Z., Li, X., Hoffman, R. M., & Glinsky, G. V. (2006) · Cell Cycle · doi:10.4161/cc.5.16.3222 · Cited by 159
Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation
Wang, X.-D., Leow, C. C., Zha, J., Tang, Z., Modrusan, Z. D., Radtke, F., Aguet, M., de Sauvage, F. J., & Gao, W. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2005.11.009 · Cited by 158
Apoptosis of circulating tumor cells in prostate cancer patients
Larson, C. J., Moreno, J. G., Pienta, K. J., Gross, S., Repollet, M., O'Hara, S. M., Russell, T. B., & Terstappen, L. W. M. M. (2004) · Cytometry Part A · doi:10.1002/cyto.a.20073 · Cited by 151
Death-From-Cancer Signatures and Stem Cell Contribution to Metastatic Cancer
Glinsky, G. V. (2005) · Cell Cycle · doi:10.4161/cc.4.9.2001 · Cited by 124
Calabrese, P. P., Tavaré, S., & Shibata, D. K. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63220-8 · Cited by 121
Ornstein, D. K., Rayford, W., Fusaro, V. A., Conrads, T. P., Ross, S., Hitt, B. A., WIGGINS, W. W., Veenstra, T. D., Liotta, L. A., & Petricoin, E. F. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000139572.88463.39 · Cited by 112
Co-ordinated changes in expression of cell adhesion molecules in prostate cancer
Murant, S. J., Handley, J., Stower, M. J., Reid, N., Cussenot, O., & Maitland, N. J. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00418-2 · Cited by 95
Self-citationTwenty Years of PSA: From Prostate Antigen to Tumor Marker.
Angelis, G. D., Rittenhouse, H. G., Mikolajczyk, S. D., Shamel, L. B., & Semjonow, A. (2007) · Europe PMC (PubMed Central) · Cited by 94
p63 in prostate biology and pathology
Grisanzio, C., & Signoretti, S. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21555 · Cited by 93
Liu, A. Y. C., Corey, E., Bladou, F., Lange, P. H., & Vessella, R. L. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960103)65:1<85::aid-ijc15>3.0.co;2-h · Cited by 83
O'Hara, S. M., Moreno, J. G., Zweitzig, D. R., Gross, S., Gomella, L. G., & Terstappen, L. W. M. M. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.028563 · Cited by 73
Chromosomal aberrations in prostate cancer
Saramäki, O. R., & Visakorpi, T. (2007) · Frontiers in bioscience · doi:10.2741/2312 · Cited by 62
Detection of tumor‐specific DNA in blood and bone marrow plasma from patients with prostate cancer
Schwarzenbach, H., Chun, F. K. ‐., Lange, I., Carpenter, S. W., Gottberg, M., Erbersdobler, A., Friedrich, M. G., Huland, H., & Pantel, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22470 · Cited by 58
Prostate Cancer Stem Cells: A Target for New Therapies
Maitland, N. J., Bryce, S. D., Stower, M. J., & Collins, A. T. (2007) · Springer eBooks · doi:10.1007/2789_2007_050 · Cited by 45
Self-citationLi, H., Zhou, J., Miki, J., Furusato, B., Gu, Y., Srivastava, S. K., McLeod, D. G., Vogel, J. C., & Rhim, J. S. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.08.011 · Cited by 39
Beyond prostate-specific antigen: alternate serum markers
Ramírez, M. L., Nelson, E. C., & Evans, C. P. (2008) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2008.2 · Cited by 35
Hall, J. A., Maitland, N. J., Stower, M., & Lang, S. (2002) · PubMed · Cited by 33
Self-citationLang, S., Smith, J., Hyde, C., Macintosh, C. A., Stower, M. J., & Maitland, N. J. (2006) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/0511080.1 · Cited by 31
Self-citationChemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?
Aragon‐Ching, J. B., & Dahut, W. L. (2007) · PubMed · Cited by 25
(2003) · PubMed
Cited by
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
Notch signalling in solid tumours: a little bit of everything but not all the time
Ranganathan, P., Weaver, K. L., & Capobianco, A. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3035 · Cited by 824
Nanomaterials in Targeting Cancer Stem Cells for Cancer Therapy
Qin, W., Huang, G., Chen, Z., & Zhang, Y. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00001 · Cited by 656
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells
Baba, T., Convery, P. A., Matsumura, N., Whitaker, R. S., Kondoh, E., Perry, T., Huang, Z., Bentley, R. C., Mori, S., Fujii, S., et al. (2009) · Oncogene · doi:10.1038/onc.2008.374 · Cited by 419
Metadata
- Authors
- Maitland, N. J., & Collins, A. T.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-06-10
- Volume
- 26
- Issue
- 17
- Pages
- 2862-2870
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2004624656
- Cited by
- 350
- References
- 66
- FWCI
- 27.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.